Guskin Gold Corp.

$ Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000147793224001919 Filed on April 08, 2024

Income Statement

Concept	2024 Q2	2023 Q4

Balance Sheet

Concept	2024 Q2	2023 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments		$4.450K
YoY Change		-92.35%
Cash & Equivalents		$4.449K
Short-Term Investments
Other Short-Term Assets		$14.02K
YoY Change		-10.64%
Inventory
Prepaid Expenses		$14.02K
Receivables
Other Receivables
Total Short-Term Assets		$18.47K
YoY Change		-74.99%
LONG-TERM ASSETS
Property, Plant & Equipment		$150.5K
YoY Change		-16.21%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets		$150.5K
YoY Change		-16.21%
TOTAL ASSETS
Total Short-Term Assets		$18.47K
Total Long-Term Assets		$150.5K
Total Assets		$169.0K
YoY Change		-33.33%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable		$485.5K
YoY Change		74.19%
Accrued Expenses		$659.4K
YoY Change		7.84%
Deferred Revenue
YoY Change
Short-Term Debt		$1.049M
YoY Change		40.25%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities		$2.561M
YoY Change		-46.1%
LONG-TERM LIABILITIES
Long-Term Debt		$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities		$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities		$2.561M
Total Long-Term Liabilities		$0.00
Total Liabilities		$2.561M
YoY Change		-46.1%
SHAREHOLDERS EQUITY
Retained Earnings		-$4.402M
YoY Change		-31.73%
Common Stock		$48.00K
YoY Change		0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity		-$2.393M
YoY Change
Total Liabilities & Shareholders Equity		$169.0K
YoY Change		-33.33%

Cashflow Statement

Concept	2024 Q2	2023 Q4

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q4	us-gaap	Assets Assets	168966	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	485462	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-2569438	usd
CY2023Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	8580	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1961034	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-4401546	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	208239	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	186950	usd
CY2023Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	150497	usd
CY2023Q3	us-gaap	Assets Noncurrent AssetsNoncurrent	186950	usd
CY2023Q3	us-gaap	Liabilities Liabilities	4823480	usd
CY2023Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies	0	usd
CY2023Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	47995	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	14020	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	150497	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	21290	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-2569438	usd
CY2023Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	243948	usd
CY2023Q4	gkin	Loan Payable Related Party Current LoanPayableRelatedPartyCurrent	152057	usd
CY2023Q3	gkin	Loan Payable Related Party Current LoanPayableRelatedPartyCurrent	153657	usd
CY2023Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	484155	usd
CY2023Q3	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	134732	usd
CY2023Q4	us-gaap	Notes Payable Current NotesPayableCurrent	412590	usd
CY2023Q3	us-gaap	Notes Payable Current NotesPayableCurrent	412000	usd
CY2023Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	367799	usd
CY2023Q3	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	3296143	usd
CY2023Q4	us-gaap	Liabilities Liabilities	2561483	usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies	0	usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	47995	usd
CY2023Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1886034	usd
CY2023Q4	us-gaap	Interest Expense InterestExpense	73551	usd
CY2022Q4	us-gaap	Interest Expense InterestExpense	25067	usd
CY2023Q4	dei	Entity Central Index Key EntityCentralIndexKey	0001509786
CY2023Q4	dei	Amendment Flag AmendmentFlag	false
CY2023Q4	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--09-30
CY2023Q4	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q4	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2023Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	47994825	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	47994825	shares
CY2023Q2	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	305047	usd
CY2023Q4	gkin	Exercise Price ExercisePrice	0.01
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2023Q4	dei	Document Type DocumentType	10-Q
CY2023Q4	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q4	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023Q4	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q4	dei	Entity File Number EntityFileNumber	333-171636
CY2023Q4	dei	Entity Registrant Name EntityRegistrantName	GUSKIN GOLD CORP.
CY2023Q4	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2023Q4	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	27-1989147
CY2023Q4	dei	Entity Address Address Line1 EntityAddressAddressLine1	4500 Great America Parkway
CY2023Q4	dei	Entity Address Address Line2 EntityAddressAddressLine2	PMB 38
CY2023Q4	dei	Entity Address Address Line3 EntityAddressAddressLine3	Ste 100
CY2023Q4	dei	Entity Address City Or Town EntityAddressCityOrTown	Santa Clara
CY2023Q4	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023Q4	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	95054
CY2023Q4	dei	City Area Code CityAreaCode	408
CY2023Q4	dei	Local Phone Number LocalPhoneNumber	766-1511
CY2023Q4	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q4	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q4	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q4	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q4	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023Q4	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023Q4	dei	Entity Shell Company EntityShellCompany	false
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	47994825	shares
CY2023Q4	us-gaap	Cash Cash	4449	usd
CY2023Q3	us-gaap	Cash Cash	58153	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	18469	usd
CY2023Q3	us-gaap	Assets Assets	208239	usd
CY2023Q4	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	659420	usd
CY2023Q3	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	583000	usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	47994825	shares
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-4498561	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-2392517	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	168966	usd
CY2023Q4	us-gaap	Share Based Compensation ShareBasedCompensation	2415	usd
CY2022Q4	us-gaap	Share Based Compensation ShareBasedCompensation	28500	usd
CY2023Q4	us-gaap	Professional Fees ProfessionalFees	29139	usd
CY2022Q4	us-gaap	Professional Fees ProfessionalFees	30440	usd
CY2023Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	48741	usd
CY2022Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	38934	usd
CY2023Q4	us-gaap	Operating Expenses OperatingExpenses	80296	usd
CY2022Q4	us-gaap	Operating Expenses OperatingExpenses	97874	usd
CY2023Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-80296	usd
CY2022Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-97874	usd
CY2023Q4	gkin	Gain Loss On Change In Fair Value Of Derivative Liability GainLossOnChangeInFairValueOfDerivativeLiability	444889	usd
CY2022Q4	gkin	Gain Loss On Change In Fair Value Of Derivative Liability GainLossOnChangeInFairValueOfDerivativeLiability	306145	usd
CY2023Q4	us-gaap	Other Income OtherIncome	0	usd
CY2022Q4	us-gaap	Other Income OtherIncome	0	usd
CY2023Q4	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	129123	usd
CY2022Q4	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	81524	usd
CY2023Q4	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	242216	usd
CY2022Q4	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	199554	usd
CY2023Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	161921	usd
CY2022Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	101680	usd
CY2023Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023Q4	us-gaap	Net Income Loss NetIncomeLoss	161921	usd
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	101680	usd
CY2023Q4	gkin	Income Loss From Continuing Operation Per Basic And Diluted Share IncomeLossFromContinuingOperationPerBasicAndDilutedShare	0.00
CY2022Q4	gkin	Income Loss From Continuing Operation Per Basic And Diluted Share IncomeLossFromContinuingOperationPerBasicAndDilutedShare	0.00
CY2023Q4	gkin	Weighted Average Number Of Shares Outstanding Basic And Diluted WeightedAverageNumberOfSharesOutstandingBasicAndDiluted	47994825	shares
CY2022Q4	gkin	Weighted Average Number Of Shares Outstanding Basic And Diluted WeightedAverageNumberOfSharesOutstandingBasicAndDiluted	47994825	shares
CY2023Q4	gkin	In Kind Contribution Of Services InKindContributionOfServices	15000	usd
CY2023Q4	us-gaap	Net Income Loss NetIncomeLoss	161921	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-2392517	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-4615241	usd
CY2022Q4	gkin	In Kind Contribution Of Services InKindContributionOfServices	15000	usd
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	101680	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-4498561	usd
CY2023Q4	us-gaap	Profit Loss ProfitLoss	161921	usd
CY2022Q4	us-gaap	Profit Loss ProfitLoss	101680	usd
CY2023Q4	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	129123	usd
CY2022Q4	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	81524	usd
CY2023Q4	gkin	Change In Fair Value Of Derivative ChangeInFairValueOfDerivative	-448659	usd
CY2022Q4	gkin	Change In Fair Value Of Derivative ChangeInFairValueOfDerivative	-306145	usd
CY2023Q4	us-gaap	Derivative Loss On Derivative DerivativeLossOnDerivative	3769	usd
CY2022Q4	us-gaap	Derivative Loss On Derivative DerivativeLossOnDerivative	0	usd
CY2023Q4	gkin	In Kind Contribution Of Service InKindContributionOfService	15000	usd
CY2022Q4	gkin	In Kind Contribution Of Service InKindContributionOfService	15000	usd
CY2023Q4	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	0	usd
CY2022Q4	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	28500	usd
CY2023Q4	us-gaap	Depreciation Depreciation	7338	usd
CY2022Q4	us-gaap	Depreciation Depreciation	7338	usd
CY2023Q4	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-4410	usd
CY2022Q4	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-7105	usd
CY2023Q4	us-gaap	Use Of Estimates UseOfEstimates	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include the assumptions used in valuation of equity-based transactions, valuation of derivative liabilities and valuation of deferred taxes.</p>
CY2023Q4	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	103485	usd
CY2022Q4	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	34751	usd
CY2023Q4	gkin	Increase Decrease In Stock Issued For Settlement Of Liabilities IncreaseDecreaseInStockIssuedForSettlementOfLiabilities	2415	usd
CY2022Q4	gkin	Increase Decrease In Stock Issued For Settlement Of Liabilities IncreaseDecreaseInStockIssuedForSettlementOfLiabilities	0	usd
CY2023Q4	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-30018	usd
CY2022Q4	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-44457	usd
CY2023Q4	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	0	usd
CY2022Q4	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	800	usd
CY2023Q4	gkin	Subscriptions On Common Stock SubscriptionsOnCommonStock	0	usd
CY2022Q4	gkin	Subscriptions On Common Stock SubscriptionsOnCommonStock	0	usd
CY2023Q4	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	usd
CY2022Q4	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	100000	usd
CY2023Q4	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	usd
CY2022Q4	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	65100	usd
CY2023Q4	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	34000	usd
CY2022Q4	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	124000	usd
CY2023Q4	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	34000	usd
CY2022Q4	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	89900	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	3982	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	45443	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	467	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	12710	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4449	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	58153	usd
CY2023Q4	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	usd
CY2022Q4	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	usd
CY2023Q4	us-gaap	Interest Paid Net InterestPaidNet	0	usd
CY2022Q4	us-gaap	Interest Paid Net InterestPaidNet	0	usd
CY2023Q4	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	0	usd
CY2022Q4	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	0	usd
CY2023Q4	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	0	usd
CY2023Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	4449	usd
CY2023Q3	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	58153	usd
CY2023Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	484155	usd
CY2023Q4	gkin	Shares Of Common Stock Issuable Upon Exercise Of Debt In Shares SharesOfCommonStockIssuableUponExerciseOfDebtInShares	60532976	shares
CY2023Q3	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	355032	usd
CY2023	gkin	Shares Of Common Stock Issuable Upon Exercise Of Debt In Shares SharesOfCommonStockIssuableUponExerciseOfDebtInShares	57429485	shares
CY2023Q3	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	355032	usd
CY2020Q3	us-gaap	Shares Issued SharesIssued	28200000	shares
CY2020Q3	gkin	Percentage Of Issued And Outstanding Shares PercentageOfIssuedAndOutstandingShares	1	pure
CY2020Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	28200000	shares
CY2020Q3	gkin	Percentage Of Issued And Outstanding Shares PercentageOfIssuedAndOutstandingShares	0.9654	pure
CY2020Q3	gkin	Description Of Share Exchange DescriptionOfShareExchange	(i) GGC’ shareholders own approximately 96.54% of the Company’s issued and outstanding common stock immediately following the effective time of the Share Exchange, and (ii) GGC’ management holds all key positions in the management of the combined company following the Closing. Under reverse recapitalization accounting, the assets and liabilities of the Company are recorded, as of the Closing, at their fair value which approximates its book value because of the short-term nature of the instruments
CY2023Q3	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets	27502	usd
CY2023Q3	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Liabilities BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities	2202101	usd
CY2023Q3	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Net BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet	-2174599	usd
CY2023Q4	us-gaap	Net Income Loss NetIncomeLoss	161921	usd
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	101680	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-4401546	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-4498561	usd
CY2023Q4	gkin	Working Capital Deficit Amount WorkingCapitalDeficitAmount	-2392518	usd
CY2023Q3	gkin	Working Capital Deficit Amount WorkingCapitalDeficitAmount	-2569438	usd
CY2023Q3	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	355032	usd
CY2022Q3	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	134732	usd
CY2023Q4	gkin	Convertible Note Issued1 ConvertibleNoteIssued1	34000	usd
CY2023	gkin	Convertible Note Issued1 ConvertibleNoteIssued1	216000	usd
CY2023Q4	gkin	Conversion Of Principal Amount ConversionOfPrincipalAmount	0	usd
CY2023	gkin	Conversion Of Principal Amount ConversionOfPrincipalAmount	0	usd
CY2023Q4	gkin	Convertible Notes Debt Discount ConvertibleNotesDebtDiscount	34000	usd
CY2023	gkin	Convertible Notes Debt Discount ConvertibleNotesDebtDiscount	216000	usd
CY2023Q4	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	129123	usd
CY2023	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	220300	usd
CY2023Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	484155	usd
CY2023Q4	gkin	Shares Of Common Stock Issuable Upon Exercise Of Debt SharesOfCommonStockIssuableUponExerciseOfDebt	60532976	shares
CY2023	gkin	Shares Of Common Stock Issuable Upon Exercise Of Debt SharesOfCommonStockIssuableUponExerciseOfDebt	57429485	shares
CY2023Q4	gkin	Estimated Market Value Of Common Stock On Measurement Date EstimatedMarketValueOfCommonStockOnMeasurementDate	0.01
CY2023	gkin	Estimated Market Value Of Common Stock On Measurement Date EstimatedMarketValueOfCommonStockOnMeasurementDate	2.5
CY2023	gkin	Exercise Price ExercisePrice	0.01
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	2.36	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	2.2730	pure
CY2023Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	367799	usd
CY2023Q3	us-gaap	Derivative Liability Fair Value Gross Asset DerivativeLiabilityFairValueGrossAsset	778688	usd
CY2023Q4	gkin	Increase Decrease In Fair Value Of Derivative Liability IncreaseDecreaseInFairValueOfDerivativeLiability	-448659	usd
CY2023Q4	us-gaap	Derivative Gain On Derivative DerivativeGainOnDerivative	37769	usd
CY2023Q4	us-gaap	Derivative Liability Fair Value Gross Asset DerivativeLiabilityFairValueGrossAsset	367799	usd
CY2023	gkin	Change In Fair Value Of Derivative Liability At The End Of The Period ChangeInFairValueOfDerivativeLiabilityAtTheEndOfThePeriod	2810680	usd
CY2023Q4	us-gaap	Gain Loss On Sale Of Derivatives GainLossOnSaleOfDerivatives	-3769	usd
CY2023Q4	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	-3255569	usd
CY2023Q4	gkin	Change In Fair Value Of Derivative Liability At The End Of The Period ChangeInFairValueOfDerivativeLiabilityAtTheEndOfThePeriod	-448659	usd
CY2023Q3	us-gaap	Derivative Liabilities DerivativeLiabilities	778688	usd
CY2022Q3	us-gaap	Derivative Liability Fair Value Gross Asset DerivativeLiabilityFairValueGrossAsset	3296143	usd
CY2023	gkin	Increase Decrease In Fair Value Of Derivative Liability IncreaseDecreaseInFairValueOfDerivativeLiability	-2873230	usd
CY2023	us-gaap	Derivative Gain On Derivative DerivativeGainOnDerivative	355775	usd
CY2023Q3	us-gaap	Derivative Liability Fair Value Gross Asset DerivativeLiabilityFairValueGrossAsset	778688	usd
CY2023	gkin	Change In Fair Value Of Derivative Liability At The Beginning Of Period ChangeInFairValueOfDerivativeLiabilityAtTheBeginningOfPeriod	8041824	usd
CY2023	us-gaap	Gain Loss On Sale Of Derivatives GainLossOnSaleOfDerivatives	77225	usd
CY2023	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	-5308369	usd
CY2023Q4	gkin	Change In Fair Value Of Derivative Liability At The Beginning Of Period ChangeInFairValueOfDerivativeLiabilityAtTheBeginningOfPeriod	2810680	usd
CY2020Q2	gkin	Common Shares Compensation Value In Shares Quarterly CommonSharesCompensationValueInSharesQuarterly	50000	shares
CY2020Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q2	us-gaap	Deferred Compensation Arrangement With Individual Common Stock Reserved For Future Issuance DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance	200000	shares
CY2020Q2	gkin	Common Shares Compensation Value CommonSharesCompensationValue	5000	usd
CY2022Q1	us-gaap	Variable Interest Entity Ownership Percentage VariableInterestEntityOwnershipPercentage	0.70	pure
CY2022Q1	gkin	Restricted Common Shares Issued Price Per Share RestrictedCommonSharesIssuedPricePerShare	1.00
CY2020Q2	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	15000000	shares
CY2020Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	15000	usd
	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	13200000	shares
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	13200	usd
CY2020Q3	us-gaap	Restricted Stock Shares Issued Net Of Shares For Tax Withholdings RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings	28200000	shares
	gkin	Proceeds From Unrelated Party ProceedsFromUnrelatedParty	110000	usd
	gkin	Exchange Of Common Shares ExchangeOfCommonShares	440000	shares
CY2021Q4	gkin	Subscription Receivable SubscriptionReceivable	75000	usd
CY2021Q4	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	300000	shares
CY2021Q4	gkin	Proceeds From Unrelated Party ProceedsFromUnrelatedParty	75000	usd
CY2021Q4	gkin	Proceeds From Unrelated Party ProceedsFromUnrelatedParty	25000	usd
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	47994825	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001

Files In Submission

Name	View Source	Status
0001477932-24-001919-index-headers.html	Edgar Link	pending
0001477932-24-001919-index.html	Edgar Link	pending
0001477932-24-001919.txt	Edgar Link	pending
0001477932-24-001919-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
gkin-20231231.xsd	Edgar Link	pending
gkin_10q.htm	Edgar Link	pending
gkin_ex311.htm	Edgar Link	pending
gkin_ex312.htm	Edgar Link	pending
gkin_ex321.htm	Edgar Link	pending
gkin_ex322.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
gkin-20231231_cal.xml	Edgar Link	unprocessable
gkin-20231231_lab.xml	Edgar Link	unprocessable
gkin-20231231_pre.xml	Edgar Link	unprocessable
gkin_10q_htm.xml	Edgar Link	completed
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
gkin-20231231_def.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

Guskin Gold Corp.

2024 Q2 Form 10-Q Financial Statement

#000147793224001919 Filed on April 08, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission